Synthesis of pentaquinoline (1) was achieved using linear solution phase iterative amide coupling as reported earlier for the shorter homologues. The starting material, methyl 8-nitro-(1H)-4-quinolinone-2-carboxylate, was generated using known procedure [3, 4, 5] which is then functionalized by introducing O-tert butyl ester as side chain. Chain elongation was achieved using successive amide coupling and nitro group reduction steps following a solution phase approach. The acid groups, which were protected as tert-butyl esters, were cleaved in the last step using a TFA cocktail [TFA/TES/DCM (dichloromethane) (95:2.5:2.5, v/v)] to give the target compound. The final compound was purified by HPLC and characterized for identity and purity (> 98%) using NMR, HPLC, and MALDI-TOF and will be reported in near future. ThT was purchased from Acros Organics (Fair Lawn, New Jersey). Both the lipids [dioleoylphosphatidylglycerol (DOPG) and dioleoylphosphatidylcholine (DOPC)] were purchased from Avanti Polar Lipids, Inc. (Alabaster, Alabama). Human IAPP (hIAPP) was synthesized by t-Boc methods and purified by the W. M. Keck facility (New Haven, Connecticut). hIAPP stock solutions were prepared using methods adapted from previous work in our lab. [6] Briefly, IAPP (~3 mg) was resolubilized in 7M guanidinium solution. The solution was filtered (0.2 micron filter) transferred to C-18 spin column, washed two times with 10% acetonitrile , 0.1% TFA in water and then two times with milliQ water and then eluted with 50% each of acetonitrile and water (200 µL) and split into aliquots. These aliquots were then lyophilized and stored at -80 ºC as powder and used fresh for every experiment. IAPP concentration was determined by absorbance measurements at 280 nm (ε = 1400 M -1 cm -1 ). Unilamellar liposomes were prepared by extrusion through a 100 nm extrusion filter. A 20 mg/mL solution of lipid, 50% DOPG:DOPC was passed through the extrusion film 21 times using a syringe extrusion device. This solution was used to prepare a buffer that would result in a final lipid concentration of 500 μg/mL for each kinetic run. The final concentration of lipid was also confirmed by measurement of total phosphorous [7, 8] which was within 0-2% error limit. All measurements were made in 50 mM sodium phosphate buffer at pH 7.4, 100 mM KCl, and 23°C. Lipid-Catalyzed Amyloid Formation Kinetics: The liposome stock solution in buffer (500 μg/mL) and 20 μM ThT were added to a Microfluor 1 black 96-well plate (Thermo Electron Corp). This was followed by addition of the small molecule inhibitors dissolved in DMSO (final DMSO concentration: 0.2%) and gentle mixing. Fiber formation was initiated by addition of hIAPP stock solution to a final concentration of 10 μM. Final volumes were 200 μL. Formation of amyloid was monitored by ThT fluorescence (Ex 450 nm and Em 485 nm) using a FluoDia T70 fluorescence plate reader (PTI) except the experiment where pentaquinoline was added in IAPP at different time frames (Fig. 3) . Data for Fig. 3 was performed on QuantaMaster C-61 fluorescence spectrometer (PTI). Kinetic experiments ( Fig. 1 and 2) were performed in triplicate, using a fourth well without hIAPP as a control blank. The data were blank subtracted, renormalized to the maximum intensity of a standard hIAPP. Reaction profiles were fit using the built in sigmoidal fit on Origin 5.0 separately for each run. This was used to extract separate t 50 values from which average and standard errors were calculated. All presented fits were normalized for clarity in the main text, and are shown uncorrected in the supplement. 
